Roy Tan, General Manager of MGI Asia Pacific, expressed his enthusiasm during the announcement, "Partnering with Dante Labs underscores our unwavering dedication to make innovative genomic technologies available globally. We are excited to quicken the pace at which these advancements become accessible in the Middle East."

Dante Genomics is a leading global genomics and precision medicine company. The company's mission, “To leverage whole genome sequencing technology and variant interpretation, so that you can make informed decisions about your health and your future”, aligns seamlessly with MGI's vision. This shared commitment forms the cornerstone of the collaboration between the two companies.

Under the partnership, MGI and Dante Labs will establish a joint demo lab and customer experience center in the Middle East. This center will provide local researchers and users with unique access to MGI's cutting-edge technology portfolio, including single cell, spatial omics, DNBSEQ platforms, laboratory automation systems, and bioinformatics products.

The collaboration will mainly focus on the creation of a customer experience center. Moreover, harnessing the power of MGI’s advanced sequencing technologies, the alliance plans to collaborate on the development and validation of whole genome and whole exome sequencing using the DNBSEQ-T7* platform, ensuring the highest standards in genomic analysis. Equipped with MGI’s automation and reagents, a regional network of sample collection centers is to be established to further expand Dante Lab’s service availability and regional coverage.

“Teaming up with MGI, our aim is to deliver superior, affordable, and flexible healthcare solutions to the Middle East, GCC, and North Africa, with the UAE as the central hub for excellence," remarked Generoso Ianniciello, Vice President of Dante Labs. "MGI‘s formidable sequencing technologies will significantly contribute to our offering, creating a strategic win-win for both organizations and extending our market presence in the region."

The partnership between MGI and Dante Labs underscores the two companies' shared vision of providing improved healthcare solutions through the adoption of genomics, striving to make advanced technology accessible, beneficial, and locally secure for all. Together, the MGI and Dante Genomics are committed to delivering on multiomics data-driven decisions for precision health, emphasizing our dedication to advancing healthcare innovation.

"We continue to enhance our vision by positioning the UAE as the premier center for Research and Diagnostics Excellence in the region, reinforcing our commitment to providing cutting-edge healthcare solutions with localized data security and safety to the UAE, Middle East, GCC, Africa and Asia," said Andrea Riposati, CEO and Co-Founder of Dante Genomics.